{"title":"慢性肾脏疾病不同阶段凝血特征的比较评价:一项横断面研究","authors":"Emelina Stambolliu , Panagiota Giannou , Aikaterini Damianaki , Maria Panagiota Terzi , Euthymia Pavlou , Elpiniki Stathopoulou , Efrossyni Nomikou , Dimitrios Petras","doi":"10.1016/j.thromres.2025.109497","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>Patients with chronic kidney disease (CKD), especially those with end stage renal disease (ESRD) are prone to both bleeding and thrombosis. We aimed to evaluate several hemostasis parameters and identify any differences in the coagulation process among patients with CKD at different stages.</div></div><div><h3>Methods</h3><div>This cross-sectional study included patients with CKD stages 2 to5 (non-dialysis) and ESRD patients on hemodialysis (HD) or peritoneal dialysis (PD). Standard coagulation tests were performed, along with thromboelastography (TEG) and platelet function analyze (PFA).</div></div><div><h3>Results</h3><div>A total of 148 patients were included in the analysis, mean age 65.6 ± 14.3 years; 75 % males; 76 % hypertensive. Significant differences were identified across all groups, particularly between CKD stages 2 and 5, in D-Dimers, FVIII, homocysteine, fibrinogen, von Willebrand factor (vWF), aPTT and TEG parameters (maximal amplitude [MA], K time, A angle), with values progressively increasing as CKD advanced (all <em>p</em> < 0.05). The PD and HD groups had major differences in FVIII, vWF, PFA and TEG parameters, with PD patients being more hypercoagulable. PFA values did not correlate with TEG parameters, while platelet count correlated with both PFA and MA values. eGFR independently predicted most of the coagulation and TEG parameters tested.</div></div><div><h3>Conclusion</h3><div>CKD progression affects TEG, PFA, and most coagulation examinations, indicating a prothrombotic profile even in the early stages of CKD. Moreover, significant differences in coagulation parameters are observed between HD and PD patients, with the latter exhibiting a more pronounced hypercoagulable state. These results should be interpreted cautiously, considering the limitations and the possible confounders of the study.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"255 ","pages":"Article 109497"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative evaluation of coagulation profiles across different stages of chronic kidney disease: A cross-sectional study\",\"authors\":\"Emelina Stambolliu , Panagiota Giannou , Aikaterini Damianaki , Maria Panagiota Terzi , Euthymia Pavlou , Elpiniki Stathopoulou , Efrossyni Nomikou , Dimitrios Petras\",\"doi\":\"10.1016/j.thromres.2025.109497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and aims</h3><div>Patients with chronic kidney disease (CKD), especially those with end stage renal disease (ESRD) are prone to both bleeding and thrombosis. We aimed to evaluate several hemostasis parameters and identify any differences in the coagulation process among patients with CKD at different stages.</div></div><div><h3>Methods</h3><div>This cross-sectional study included patients with CKD stages 2 to5 (non-dialysis) and ESRD patients on hemodialysis (HD) or peritoneal dialysis (PD). Standard coagulation tests were performed, along with thromboelastography (TEG) and platelet function analyze (PFA).</div></div><div><h3>Results</h3><div>A total of 148 patients were included in the analysis, mean age 65.6 ± 14.3 years; 75 % males; 76 % hypertensive. Significant differences were identified across all groups, particularly between CKD stages 2 and 5, in D-Dimers, FVIII, homocysteine, fibrinogen, von Willebrand factor (vWF), aPTT and TEG parameters (maximal amplitude [MA], K time, A angle), with values progressively increasing as CKD advanced (all <em>p</em> < 0.05). The PD and HD groups had major differences in FVIII, vWF, PFA and TEG parameters, with PD patients being more hypercoagulable. PFA values did not correlate with TEG parameters, while platelet count correlated with both PFA and MA values. eGFR independently predicted most of the coagulation and TEG parameters tested.</div></div><div><h3>Conclusion</h3><div>CKD progression affects TEG, PFA, and most coagulation examinations, indicating a prothrombotic profile even in the early stages of CKD. Moreover, significant differences in coagulation parameters are observed between HD and PD patients, with the latter exhibiting a more pronounced hypercoagulable state. These results should be interpreted cautiously, considering the limitations and the possible confounders of the study.</div></div>\",\"PeriodicalId\":23064,\"journal\":{\"name\":\"Thrombosis research\",\"volume\":\"255 \",\"pages\":\"Article 109497\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombosis research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049384825002476\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049384825002476","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Comparative evaluation of coagulation profiles across different stages of chronic kidney disease: A cross-sectional study
Background and aims
Patients with chronic kidney disease (CKD), especially those with end stage renal disease (ESRD) are prone to both bleeding and thrombosis. We aimed to evaluate several hemostasis parameters and identify any differences in the coagulation process among patients with CKD at different stages.
Methods
This cross-sectional study included patients with CKD stages 2 to5 (non-dialysis) and ESRD patients on hemodialysis (HD) or peritoneal dialysis (PD). Standard coagulation tests were performed, along with thromboelastography (TEG) and platelet function analyze (PFA).
Results
A total of 148 patients were included in the analysis, mean age 65.6 ± 14.3 years; 75 % males; 76 % hypertensive. Significant differences were identified across all groups, particularly between CKD stages 2 and 5, in D-Dimers, FVIII, homocysteine, fibrinogen, von Willebrand factor (vWF), aPTT and TEG parameters (maximal amplitude [MA], K time, A angle), with values progressively increasing as CKD advanced (all p < 0.05). The PD and HD groups had major differences in FVIII, vWF, PFA and TEG parameters, with PD patients being more hypercoagulable. PFA values did not correlate with TEG parameters, while platelet count correlated with both PFA and MA values. eGFR independently predicted most of the coagulation and TEG parameters tested.
Conclusion
CKD progression affects TEG, PFA, and most coagulation examinations, indicating a prothrombotic profile even in the early stages of CKD. Moreover, significant differences in coagulation parameters are observed between HD and PD patients, with the latter exhibiting a more pronounced hypercoagulable state. These results should be interpreted cautiously, considering the limitations and the possible confounders of the study.
期刊介绍:
Thrombosis Research is an international journal dedicated to the swift dissemination of new information on thrombosis, hemostasis, and vascular biology, aimed at advancing both science and clinical care. The journal publishes peer-reviewed original research, reviews, editorials, opinions, and critiques, covering both basic and clinical studies. Priority is given to research that promises novel approaches in the diagnosis, therapy, prognosis, and prevention of thrombotic and hemorrhagic diseases.